Background. The pandemic spread of antibiotic resistance increases the likelihood of ineffective empirical therapy. The recently emerged fluoroquinolone-resistant Escherichia coli sequence type (ST) 131-H30R subclone (H30) is a leading cause of multidrug-resistant urinary tract infection (UTI) and bloodstream infection worldwide.
Antimicrobial resistance is currently one of the most challenging problems in medicine [1] [2] [3] [4] . The spread of multidrug-resistant microorganisms increases the risk that empirically (ie, prior to susceptibility testing results) prescribed antibiotic therapy will be ineffective. Such mismatched antimicrobial therapy prolongs patient suffering and increases the rates of complications, hospitalization, and, with severe infections, mortality [5] [6] [7] .
Urinary tract infection (UTI) is among the most common types of bacterial infection in the developed world [8, 9] , resulting in >10 million healthcare visits in the United States alone [10] . Catheter-associated UTI is among the main nosocomial infections, accounting for 13%-17% of cases [11] . UTI is also the second most common infection (after respiratory tract infections) in emergency department patients [12] . Because UTI is common and is routinely treated with antibiotics, it represents one of the main reasons for antibiotic prescriptions overall.
Escherichia coli is the leading cause of UTI and the main target for empirical treatment of suspected UTI [6] . In the late 1990s, H30R, a novel fluoroquinolone-resistant strain of E. coli from the sequence type 131 (ST131) clonal group, emerged and spread around the globe in a pandemic fashion [13] . It acquired resistance to other classes of antibiotics, including production of CTX-M15 extended-spectrum β-lactamase (ESBL) by its subclone, H30Rx [14] . The ST131-H30R/Rx clone, hereafter termed H30, is currently responsible for the bulk of multidrug-resistant UTIs and bloodstream infections in both developed and developing countries. The H30-specific fraction of E. coli infections is especially high among patients who are hospitalized or in long-term care facilities; other important risk factors include older age, male gender, and compromised host defenses [15] . H30 is also associated with a higher rate of persistent UTI and adverse outcomes that cannot be explained entirely by its antimicrobial resistance and association with compromised hosts [13, 15] .
Despite the widespread occurrence of H30, its relative contribution to mismatched empirical antibiotic prescribing has not been evaluated. Moreover, the prevalence of H30 has not been evaluated in patients presenting to an emergency department or urgent care clinic with UTI, which is one of the leading reasons for emergency department visits and subsequent hospitalization. Here, we investigated the prevalence of H30 among patients with suspected UTI in an urgent care setting, its association with a wide range of relevant host characteristics, and its contribution to antibiotic/pathogen mismatch with empirical therapy.
METHODS

E. coli Urine Isolates
The 306 E. coli study isolates were collected within a previously reported prospective clonal diagnostic study [16] , which was done from July 2014 to November 2015 at the Kaiser Permanente Washington (KPWA) urgent care clinic (UCC, Capitol Hill, Seattle), assisted by the KPWA central laboratory (Tukwila, Washington) and the Department of Microbiology, University of Washington (UW; Sokurenko laboratory). The KPWA Institutional Review Board granted a waiver of consent for collection and use of the samples.
Study participants were men and women aged 18 and older, admitted to the UCC with symptoms that prompted a dipstick urinalysis (Bayer Multistix strips) for suspected UTI. During the study, 750 total urinalysis-positive samples underwent standardized quantitative culture, species identification, and susceptibility testing at both the KPWA central laboratory and UW (research laboratory).
Laboratory Analysis
Quantitative urine culture and species identification was done in the research laboratory using HardyCHROM UTI selective agar plates (Hardy Diagnostic). Escherichia coli-positive urine samples were analyzed as follows. From each sample, 2-4 arbitrarily selected single colonies underwent clonotyping using a previously described 7-SNP test [17] : In brief, this polymerase chain reaction-based test determines the presence/absence of 7 single-nucleotide polymorphisms (ie, 7-SNP) in fumC and fimH (used in the fumC/fimH [CH] sequence typing scheme for E. coli [18, 19] ), thus assigning an isolate to a distinct clonotype (CT) with a triple-number designator (eg, CT561). The identity of putative ST131-H30 isolates (per the 7-SNP test) was further confirmed by CH sequence typing. Susceptibility to 12 antibiotics (representing 8 drug classes) and production of ESBLs was tested by disk diffusion according to Clinical and Laboratory Standards Institute guidelines [20] . Multidrug resistance was defined as resistance to ≥3 antimicrobial classes.
Medical Records Review
Source patients' electronic medical records were reviewed to extract age, gender, and all diagnosis codes and prescriptions from 1 month before to 2 months after the index UCC visit. Urinary catheter use was inferred from diagnoses entered at or before the index visit, diabetes from any corresponding diagnosis, and prior antibiotic use from prescription of any antibiotic between 30 and 2 days before the index visit.
Statistical Analysis
Statistical analysis was performed using Stata/IC 14.0 software (StataCorp, College Station, Texas). Two-by-two comparisons were performed using the χ 2 ] CFU/mL, respectively; P = .50). Thus, H30 subclone was the most prevalent clonal group, occurring in approximately 1 of 7 patients with E. coli bacteriuria.
H30 Subclone Prevalence in Relation to Age
To analyze H30 in relation to age, we plotted the cumulative age distribution functions for patients with H30 and non-H30 urinary E. coli, performing a K-S test. The K-S test showed that patients with H30 tend to be older (P = .001), with the largest K-S statistic (D = 0.37) calculated for the age of 70 years ( Figure 1B ). H30 was significantly more prevalent among older patients (aged ≥70) than younger patients (aged 18-69) with E. coli bacteriuria (26% vs 9%, P < .001). Thus, among UCC patients with E. coli bacteriuria, the H30 subclone was closely associated with older age, occurring in 1 of 4 of patients ≥70 years old.
Association of H30 With Patient Characteristics
We next determined whether the association of H30 with older age involved other patient characteristics, including gender and clinical factors such as diabetes, urinary catheter use, and prior antibiotic prescriptions (Table 1) . H30 was associated significantly with diabetes and urinary catheter use in both age groups, and with male gender and prior antibiotic use among younger patients only. After multivariable adjustment, older age, diabetes, and urinary catheter use remained significant predictors of H30 isolation, whereas male gender and antibiotic use lost statistical significance (Table 2 ). Thus, among UCC patients with E. coli bacteriuria, older age, diabetes, and urinary catheter use were independent predictors of having H30.
Contribution of H30 to Antimicrobial Resistance
The prevalence of antibiotic resistance was generally higher among E. coli isolates from older as opposed to younger patients (Table 3) . This difference was statistically significant for ciprofloxacin (32% vs 16%, P < .01) and multidrug resistance (19% vs 10%, P = .03), borderline for cefazolin (13% vs 6%, P = .09) and fosfomycin (5% vs 1%, P = .09), and numerically evident for ESBL production and all other agents except trimethoprim-sulfamethoxazole (TMP-SMX).
Nearly all resistance phenotypes were significantly more prevalent among H30 isolates than non-H30 isolates, both overall and within each age group (Table 3) . The most dramatic difference involved ciprofloxacin resistance: Although accounting for only 16% of all isolates, H30 comprised 68% (43/63) of ciprofloxacin-resistant isolates, 62% (8/14) of ESBL-producing isolates, and 55% (21/38) of multidrug-resistant isolates. Although differences did not achieve statistical significance, for all agents except fosfomycin resistance prevalence tended to be numerically higher among H30 isolates from older as opposed to younger patients (Table 3) . Interestingly, the age-vs-resistance relationship among non-H30 isolates was the opposite, with resistance being numerically more prevalent among younger patients for 7 of the 10 studied resistance phenotypes. Consequently, the fold-difference in resistance prevalence between H30 and non-H30 isolates was most dramatic among older patients, where it was 2-fold for ampicillin, 2.5-fold for TMP-SMX, 5-fold for amoxicillin-clavulanate, and 9-fold for multidrug resistance. Furthermore, among older patients ESBL production was limited to H30 isolates. Thus, H30 was by far the main contributor to antimicrobial resistance among E. coli urine isolates from UCC patients and was solely responsible for the higher overall resistance prevalence among isolates from older vs younger patients.
Impact of E. coli H30 on Antibiotic/Pathogen Mismatches
Overall, 246 of the 306 (80%) UCC patients with E. coli bacteriuria were prescribed an antibiotic on the day of the index visit. The most frequently prescribed antibiotics were fluoroquinolones (52%), TMP-SMX (28%), first-generation cephalosporins (8%), and nitrofurantoin (6%) (Supplementary Table 1 ). The only statistically significant age-related differences in prescription patterns were that older patients, compared with younger patients, more frequently received cephalosporins (P < .01) and less frequently received TMP-SMX (P = .04). Prescription patterns did not differ significantly between patients with H30 vs non-H30 isolates (Supplementary Table 1 ).
For 40 of the 246 (16.3%) patients who received an antibiotic prescription, the urine E. coli isolate was resistant in vitro to the prescribed antibiotic, resulting in an antibiotic/pathogen mismatch (Table 4) . Antibiotic/pathogen mismatches were significantly more frequent among older (20/71 [28%]) than younger (20/175 [11%]) patients (P < .01), and were due largely to H30 ( Table 4) . That is, regardless of patient age, antibiotic/pathogen mismatch was nearly 10 times more likely with H30 isolates (71% overall; 78% among older patients, 62% among younger patients) than with non-H30 isolates (8.4% overall; 11.3% among older patients, 7.4% among younger patients) (P < .001, overall and within each age group). Furthermore, H30 was responsible for 55% of antibiotic/pathogen mismatch overall, including 40% among younger and 70% among older patients. Antibiotic/pathogen mismatches were also associated with the 2 other host risk factors for H30, both singly and in combination with one another and/or older age. Specifically, antibiotic/pathogen mismatch occurred in 30% (8/27) of patients with diabetes and 60% (3/5) of those with a urinary catheter (Table 4) , all due to H30. It also occurred in 26% (21/82) of those with at least 1 such host risk factor (older age, diabetes, and/or catheter use), of which 71% (15/21) were due to H30, and 45% (9/20) of those with at least 2 such risk factors, of which all (9/9) were due to H30. Thus, H30 was the single largest contributor to antibiotic/pathogen mismatches overall, and was responsible for most mismatches among older patients and those with diabetes and/or urinary catheter use.
H30 Prevalence Among All Urinalysis-positive Patients With Risk Factors for H30
The above analyses were limited to urinalysis-positive patients who proved later to have E. coli bacteriuria, yet at the time of presentation these patients were indistinguishable from other urinalysis-positive patients. For a more realistic operational perspective, we estimated the probability of H30 occurrence among all urinalysis-positive urine samples for UCC patients with 1 or more of the identified risk factors for H30 (older age, diabetes, and catheter use; Table 5 ). Although among the source patients for the 750 urinalysis-positive urine samples H30 was present in only 6% overall, it was isolated from 11% of older patients, 17% of those with diabetes, and 19% of those with a urinary catheter. The likelihood of H30 doubled from baseline (from 6% to 11%) if at least 1 such risk factor was present, and doubled again (to 24%) if 2 or more risk factors were present.
Thus, in certain subsets of patients with a positive urinalysis, H30 occurs in 1 in 4 cases.
DISCUSSION
We demonstrate here that the recently emerged H30 subclone of E. coli ST131 is associated with mismatched empirical antimicrobial prescriptions for treatment of E. coli bacteriuria in an urgent care population, especially in patients with readily identifiable risk factors such as older age, diabetes, and urinary catheter use. Notably, a recent study demonstrated that the ≥70 years age group has had the largest increase since 1998 in UTI-related hospitalizations in the United States [22] . This could, at least partially, reflect the fact that this age group is the primary target for the H30 clone that spread globally in the first decade of this century, raising the rate of treatment errors and more frequently causing persistent infections and adverse outcomes.
The high rate of mismatched prescriptions associated with H30 bacteriuria can be attributed to this subclone's notoriously extensive antibiotic resistance profile [15, 23] . Our study confirms that among UCC patients antibiotic resistance is significantly more prevalent for several antibiotic classes among H30 isolates as compared to other E. coli, usually independent of age group. Although H30 is best known for its uniform resistance to fluoroquinolones, many of its members are also resistant to other drugs commonly prescribed for UTI such as TMP-SMX and β-lactams, including third-generation cephalosporins. Indeed, 20% of the present H30 isolates were ESBL producers, as compared with <3% of non-H30 isolates. While resistance to nitrofurantoin and fosfomycin also was more common for H30, its overall resistance to those antibiotics was generally well below 10%. Despite recommendations against fluoroquinolones as firstor second-choice regimens for uncomplicated UTI [6] , their overuse is common [24] [25] [26] , possibly due to a perception that these drugs are both safe and more effective than other drugs. Nitrofurantoin, an antibiotic of choice for uncomplicated UTI [6] , here was prescribed for only 6% of patients. Nitrofurantoin is used relatively infrequently in the United States and abroad [24, 27] , possibly due to its longer treatment durations (as compared with fluoroquinolones or TMP-SMX), lower efficacy and greater toxicity in patients with renal insufficiency [28] , and relatively narrow spectrum of activity. Our data suggest that nitrofurantoin would be attractive for use in UCC patients with suspected UTI if a rapid test were to detect H30. This applies also to fosfomycin, which is not used widely [24, 29, 30] , possibly due to limited experience in the United States, high cost, and mixed opinion about efficacy against UTI relative to nitrofurantoin [31, 32] . Preferential use of nitrofurantoin or fosfomycin for infections likely due to H30 is especially important, considering that H30 exhibits uniform resistance to fluoroquinolones and a 30% resistance prevalence for TMP-SMX and narrow-spectrum cephalosporins. Thus, the persistence of empirical use of fluoroquinolones for UTI in the United States is not only ineffective but harmful, leading to the co-selection of H30 in particular and multidrug resistance in general; it could well have been one of the major reasons for the above-mentioned increased hospitalization rate among UTI patients that was associated with the fluoroquinolone resistance of H30.
In view of the significant impact of H30 on mismatched antimicrobial selection for UCC patients, a point-of-care diagnostic test that could identify H30 directly in patients' urine could be highly beneficial. Development of such a rapid ST131-H30-specific urine test was reported previously [15, 33] . Here, we estimated how often H30 could be isolated in different categories of patients presenting to urgent care with suspected UTI. We found previously that the urinalysis test used here (see Methods) was 98% sensitive for E. coli bacteriuria [16] . Thus, H30 detection is relevant for patients with a positive urinalysis. By contrast, urinalysis was only 41% specific for E. coli bacteriuria, presumably due to other uropathogens or nonbacterial causes of an abnormal urinalysis result. We found that among UCC patients with positive urinalysis, certain patient subsets had a significantly higher risk of having H30 than did the overall population (6%), including patients ≥70 years of age (11%) or with diabetes (17%), a urinary catheter (19%), or 2 or more risk factors (23%). The latter value is twice that among all older patients and 8 times that among "no risk factor" patients. Thus, certain risk groups-some of which are sizeable-have a high chance of having urinary H30, detection of which could meaningfully reduce the mismatched prescription rate.
The practical significance of point-of-care detection of urinary H30 strains would depend on the benefits and harms of reducing mismatched empiric prescription and of fluoroquinolone use, including less selection for resistance. In recent studies of patients with suspected UTI, inappropriate drug selection was strongly associated with return visits to an emergency department or urgent care clinic [34] . Emergency department visits are significantly more expensive than outpatient office visits, costing on average more than $2000 [35, 36] . Because ineffective UTI treatment may also result in higher hospital admission rates or prolonged hospital stays, as demonstrated specifically for H30 [23] , the cost of mismatched prescription could be very high, which could justify the introduction of point-of-care precision diagnostic tests to minimize their occurrence. Finally, because H30 is associated with adverse clinical outcomes independent of its resistance [15] , recognition of its presence conceivably could directly benefit the clinical management of high-risk patients, although this remains to be demonstrated. Moreover, even in the absence of specific diagnostic tests, it would be appropriate to treat patients who belong to the risk groups described here (elderly and/or suffering from diabetes and/or using urinary catheter) as likely exposed to H30 infection and, thus, if possible, to prescribe nitrofurantoin, fosfomycin or, with caution, third-generation cephalosporins-but not fluoroquinolones, to which resistance is universal, or TMP-SMX, to which resistance is very common. Considering H30's tendency to cause repeated infection and severe complications independently of drug-bug mismatch, such patients also might need closer surveillance for these sequelae.
The only other clonally related bacterial isolates that have been shown to contribute to mismatched empirical antibiotic prescriptions in similar proportions is methicillin-resistant Staphylococcus aureus (MRSA). While specific treatments, tests, and surveillance measures have been developed for MRSA, there has not been such in-depth focus on H30, likely because H30 emerged much more recently than MRSA and its tight clonal nature was recognized only within the past decade.
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